Ardent Health (ARDT) Stock Price, News & Analysis

Company Overview

Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.

Key Stats

• Today's Range: $10.10 to $10.60
• 50-Day Range: $10.21 to $14.89
• 52-Week Range: $10.10 to $20.72
• Volume: 470,053 shs
• Average Volume: 470,005 shs
• Market Capitalization: $1.46 billion
• P/E Ratio: 6.26
• Dividend Yield: N/A
• Price Target: $20.30
• Consensus Rating: Moderate Buy

Ardent Health Stock Analysis - MarketRank™

Ardent Health scored higher than 72% of companies evaluated by MarketBeat, and ranked 259th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ardent Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 9 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Ardent Health has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 59.35%

Earnings Growth

Earnings for Ardent Health are expected to grow by 59.35% in the coming year, from $1.23 to $1.96 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ardent Health is 6.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.09.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ardent Health is 6.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.67.

Price to Earnings Growth Ratio

Ardent Health has a PEG Ratio of 4.44. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Ardent Health has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ARDT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ardent Health does not currently pay a dividend.

Dividend Growth

Ardent Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ARDT.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.62

News Sentiment

Ardent Health has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Ardent Health this week, compared to 4 articles on an average week.

MarketBeat Follows

6 people have added Ardent Health to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ardent Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.70% of the stock of Ardent Health is held by insiders.

ARDT Stock Analysis - Frequently Asked Questions

How have ARDT shares performed this year?

Ardent Health's stock was trading at $17.08 at the beginning of 2025. Since then, ARDT shares have decreased by 40.2% and is now trading at $10.21.

How were Ardent Health's earnings last quarter?

Ardent Health, Inc. (NYSE:ARDT) issued its quarterly earnings results on Tuesday, May, 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.21 by $0.08. The company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.50 billion. Ardent Health had a trailing twelve-month return on equity of 16.07% and a net margin of 3.73%.
Read the conference call transcript.

When did Ardent Health IPO?

Ardent Health (ARDT) raised $192 million in an IPO on Thursday, July 18th 2024. The company issued 12,000,000 shares at a price of $16.00 per share.

Who are Ardent Health's major shareholders?

Top institutional investors of Ardent Health include Allspring Global Investments Holdings LLC (0.58%), Peregrine Capital Management LLC (0.22%), Wedge Capital Management L L P NC (0.07%) and Oliver Luxxe Assets LLC (0.06%).

How do I buy shares of Ardent Health?

Shares of ARDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ardent Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ardent Health investors own include Broadcom (AVGO), 4D Molecular Therapeutics (FDMT), Mirum Pharmaceuticals (MIRM), Micron Technology (MU), Uber Technologies (UBER), Advanced Micro Devices (AMD) and ASML (ASML).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 8/01/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NYSE:ARDT
• Previous Symbol: NYSE:ARDT
• CIK: 1756655
• Web: N/A
• Phone: (615) 296-3000
• Fax: N/A
• Employees: 24,900
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Ardent Health: $20.30
• High Price Target: $25.00
• Low Price Target: $14.60
• Potential Upside/Downside: +98.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.63
• Trailing P/E Ratio: 6.26
• Forward P/E Ratio: 8.30
• P/E Growth: 4.48
• Net Income: $210.34 million
• Net Margins: 3.73%
• Pretax Margin: 6.32%
• Return on Equity: 16.07%
• Return on Assets: 4.69%

Debt

• Debt-to-Equity Ratio: 0.70
• Current Ratio: 2.12
• Quick Ratio: 1.98

Sales & Book Value

• Annual Sales: $5.97 billion
• Price / Sales: 0.24
• Cash Flow: $2.43 per share
• Price / Cash Flow: 4.21
• Book Value: $10.66 per share
• Price / Book: 0.96

Miscellaneous

• Outstanding Shares: 143,040,000
• Free Float: 140,612,000
• Market Cap: $1.46 billion
• Optionable: Optionable
• Beta: N/A